-86%

est. 2Y upside i

HealthcareSeed

Software to launch and integrate genetics into clinical care

Rank

#825

Sector

HealthTech

Est. Liquidity

~4Y

Data Quality

Data: Low

Nest Genomics presents a moderate upside opportunity for a job seeker, balanced by a higher risk profile typical of an early-stage HealthTech company.

Last updated: February 25, 2026

Bull (20%)+350%

Nest Genomics successfully expands its EHR integrations and leverages key partnerships (like Genome Medical and athenahealth) to become a dominant software platform for longitudinal genomic programs. Revenue scales to $20M+ by 2028, justifying a $200M+ valuation (4.4x current) at a 10x revenue multiple, driven by strong market adoption and high switching costs.

Base (45%)+120%

Nest Genomics achieves steady growth, securing additional health system customers and expanding its platform capabilities. It maintains its niche but faces ongoing competition. Revenue reaches $5M-$7M by 2028, leading to an acquisition or Series B round at a $100M valuation (2.2x current), reflecting solid execution but limited market dominance.

Bear (35%)-80%

Dominant EHR vendors like Epic or Cerner develop or acquire competing genomic integration platforms, severely limiting Nest's market penetration and growth. Alternatively, a well-funded competitor gains significant traction. Revenue stalls below $2M, leading to a down round or limited exit at a $9M valuation, wiping out most common stock value due to liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors have contributed $9M in total funding, representing 20% of the estimated current $45M valuation, indicating a meaningful liquidation preference ahead of common stock.

Dilution Risk

high

As an early-stage company, Nest Genomics will likely require multiple additional funding rounds (Series A, B, etc.) to scale, which will lead to significant future dilution for current equity holders.

Secondary Liquidity

none

Given its early stage and small size, there is currently no active secondary market or tender offers for Nest Genomics' equity.

Questions to Ask at the Interview

Strategic questions based on Nest Genomics's data — designed to show you've done your homework.

  • 1

    “Given the significant threat from dominant EHR vendors like Epic and Cerner, how is Nest Genomics planning to differentiate and defend its market position against potential in-house solutions or acquisitions by these incumbents?”

  • 2

    “With current revenue around $588k, what are the key milestones and growth strategies Nest Genomics aims to achieve over the next 12-24 months to significantly scale its customer base and revenue, particularly leveraging partnerships like athenahealth?”

  • 3

    “Considering the seed funding round was in early 2023, what is the anticipated timeline for the next funding round (Series A/B), and how does the company envision employee equity (RSUs/options) being valued and potentially liquid over a 2-5 year horizon?”

Community

Valuation Sentiment

Our model estimates -86% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.